Inventor · disambiguated record
Jerry Evarts
Also filed as: EVARTS JERRY · EVARTS JERRY B · EVARTS JR JERRY B
28 granted patents·9 pending applications·146 citations·filing 2003–2024
96Inventor score
Top patents by PatentIndex Score
37 records- 0194US8865730B2Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-oneGILEAD CALISTOGA LLC·Filed 2013·Granted Oct 21, 2014·25 cites·12 claims
- 0293US9796721B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2016·Granted Oct 24, 2017·12 cites·17 claims
- 0391US10059677B2Process for preparing phosphatidylinositol 3-kinase inhibitors and intermediates thereofGILEAD CALISTOGA LLC·Filed 2016·Granted Aug 28, 2018·8 cites·14 claims
- 0491US9765060B2Phosphatidylinositol 3-kinase inhibitorsGILEAD SCIENCES INC·Filed 2015·Granted Sep 19, 2017·13 cites·2 claims
- 0590US10047060B2Process methods for phosphatidylinositol 3-kinase inhibitorsGILEAD CALISTOGA LLC·Filed 2017·Granted Aug 14, 2018·7 cites·2 claims
- 0689US9567337B2Process methods for phosphatidylinositol 3-kinase inhibitorsGILEAD CALISTOGA LLC·Filed 2014·Granted Feb 14, 2017·10 cites·44 claims
- 0788US10414737B2Process methods for phosphatidylinositol 3-kinase inhibitorsGILEAD CALISTOGA LLC·Filed 2018·Granted Sep 17, 2019·5 cites·24 claims
- 0888US9708327B2Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-oneGILEAD CALISTOGA LLC·Filed 2014·Granted Jul 18, 2017·12 cites·47 claims
- 0988US9469643B2Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-oneGILEAD CALISTOGA LLC·Filed 2014·Granted Oct 18, 2016·9 cites·6 claims
- 1088US9029384B2Phosphatidylinositol 3-kinase inhibitorsGILEAD CALISTOGA LLC·Filed 2013·Granted May 12, 2015·10 cites·16 claims
- 1187US9221795B2Phosphatidylinositol 3-kinase inhibitorsGILEAD SCIENCES INC·Filed 2014·Granted Dec 29, 2015·9 cites·59 claims
- 1284US10730879B2Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-oneGILEAD CALISTOGA LLC·Filed 2016·Granted Aug 4, 2020·2 cites·4 claims
- 1382US9266878B2Phosphatidylinositol 3-kinase inhibitorsEVARTS JERRY·Filed 2015·Granted Feb 23, 2016·7 cites·17 claims
- 1482US2024199622A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1581US10442805B2Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-oneGILEAD CALISTOGA LLC·Filed 2017·Granted Oct 15, 2019·3 cites·1 claims
- 1678US11820777B2Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2022·Granted Nov 21, 2023·0 cites·27 claims
- 1778US10167291B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2017·Granted Jan 1, 2019·1 cites·28 claims
- 1877US10954199B2Process methods for phosphatidylinositol 3-kinase inhibitorsGILEAD CALISTOGA LLC·Filed 2019·Granted Mar 23, 2021·0 cites·20 claims
- 1977US9018221B2Phosphatidylinositol 3-kinase inhibitorsGILEAD CALISTOGA LLC·Filed 2013·Granted Apr 28, 2015·3 cites·13 claims
- 2076US10221197B2Phosphatidylinositol 3-kinase inhibitorsGILEAD SCIENCES INC·Filed 2015·Granted Mar 5, 2019·2 cites·13 claims
- 2176US8440677B2Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of useEVARTS JERRY B·Filed 2010·Granted May 14, 2013·5 cites·14 claims
- 2272US12448387B2Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yljimidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamideACERTA PHARMA BV·Filed 2024·Granted Oct 21, 2025·0 cites·31 claims
- 2371US11059829B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleateACERTA PHARMA BV·Filed 2020·Granted Jul 13, 2021·0 cites·42 claims
- 2471US10640509B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphomaACERTA PHARMA BV·Filed 2018·Granted May 5, 2020·0 cites·20 claims
- 2571US2022177476A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 2670US12024520B2Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamideACERTA PHARMA BV·Filed 2019·Granted Jul 2, 2024·1 cites·29 claims
- 2767US10308639B2Phosphatidylinositol 3-kinase inhibitorsGILEAD SCIENCES INC·Filed 2015·Granted Jun 4, 2019·1 cites·20 claims
- 2863US8546409B2Methods of treatment for solid tumorsPURI KAMAL D·Filed 2010·Granted Oct 1, 2013·1 cites·25 claims
- 2950US10858364B2Imidazopyrazine inhibitors of Bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2017·Granted Dec 8, 2020·0 cites·14 claims
- 3048US2013143902A1Compositions and methods of treating a proliferative disease with a quinazolinone derivativeGILEAD CALISTOGA LLC·Filed 2012·Application pending·0 cites
- 3148US2013344138A1Methods of treatment for solid tumorsGILEAD CALISTOGA LLC·Filed 2013·Application pending·0 cites
- 3248US2018065953A1Phosphatidylinositol 3-kinase inhibitorsGILEAD SCIENCES INC·Filed 2017·Application pending·0 cites
- 3343US2016039793A1Phosphatidylinositol 3-kinase inhibitorsGILEAD SCIENCES INC·Filed 2015·Application pending·0 cites
- 3441US2016016915A1Phosphatidylinositol 3-kinase inhibitorsGILEAD CALISTOGA LLC·Filed 2015·Application pending·0 cites
- 3541US2014235643A1Novel quinoxaline inhibitors of pi3kGILEAD CALISTOGA LLC·Filed 2012·Application pending·0 cites
- 3635US2013324561A1Atropisomers of p13k-inhibiting compoundsEVARTS JERRY·Filed 2011·Application pending·0 cites
- 3734US7501535B2Chemical synthons and intermediatesPURDUE RESEARCH FOUNDATION·Filed 2003·Granted Mar 10, 2009·0 cites·20 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →